'AI is only as smart as the data and the people behind it', says Kyle Ryan

Media 7 | May 17, 2023 | Read Time : 7:06 min

Unveiling AI's Potential: Kyle Ryan Insights on Data and Ingenuity
Kyle Ryan believes that innovative concepts, data-driven insights, precise engineering, and efficient execution combine to create great products. He also believes that leadership is essential for innovation. Read on to know his thoughts on the role of leadership and technology in healthcare industry.

A leader is there to serve others, and I put it into distinct practice.

Media 7: How have your leadership style and people management skills evolved over the course of your inspiring career trajectory?
Kyle Ryan:
As I’ve grown my career over the past two decades, what has become most apparent to me and most important to my leadership style is how much people matter. When I started at Sony, I grew a lot as a leader going from a front line worker and young engineer to a relatively high leadership position as the VP of Technology. That role really honed in on the importance of being people-oriented. I'm a very big advocate of servant leadership, meaning a leader is there to serve others, and I put it into distinct practice as I oversaw a team of more than 750 individuals with very diverse backgrounds and in various types of roles. I strive to instill a culture of servant leadership amongst my leadership team and all levels of management to enable them to worry less about their own success and more about the success of the people they serve. My people management skills have definitely continued to mature and evolve throughout my career. And all of that has led me to this role. It’s led me to be able to apply some of those things that I learned from others, as naturally, you learn from all those that you work with, and work for, over the course of your career. It's very rewarding to see people improve, to help them through challenges, and to help them grow their careers and see their own progression.

M7: What are some of the biggest trends and challenges that CTOs from the world of medicine face today?
KR:
One of the biggest challenges is around the interoperability of healthcare data. There is currently a significant focus on interoperability in the US. But the reality is, it's going to take decades to solve, and will really require some true innovation, creative thinking, and collaboration. Now, governments are stepping in to try and encourage this cooperation by setting certain types of rules and regulations. I think, in the end, interoperability will require us all, in the private sector, to embrace data sharing and standardization, and to an extent, self-monitor this exercise so that it can become a reality.

It's very arduous today for patients to have a seamless healthcare experience with the various doctors they see who are using different types of technology systems. Not being able to treat a patient holistically can mean that patient outcomes suffer as disparate systems can be less reliable and more cumbersome for providers.

The other challenge we face is on the clinical side. Doctors today are frustrated, because they're actually less efficient with software than they are with a pen and paper. It's our responsibility, as technologists and owners of the software and software development, to make the software solution as fast and convenient as a pen and a piece of paper. We need to ensure the software has all the other benefits that come from the fact that it is digital, searchable, and reportable, unlike a pen and a piece of paper. Our goal is to allow providers to focus on their patients and not on the computer.

M7: Kindly share your thoughts on how the rise of telemedicine and remote care is impacting the healthcare industry?
KR:
The silver lining to the COVID-19 pandemic was the adoption of virtual visits, and the convenience that it provides. The efficiency that telemedicine provides to both the practice provider and the patient is a really cool win. I believe it's here to stay. Naturally, more of the in-person appointments have come back as pandemic restrictions have lessened. But we still see most practices on a daily basis leverage remote care systems, tele health being one of those. As we introduce more high-competence technology, wearables, and other devices that can provide confidence and trusted data, our challenge is to make sure our software integrates with those, and stays ahead as those trends continue to evolve.

Read more: Q&A with Matthew Sappern, CEO at PeriGen


I think interoperability has also continued to be reinforced by the results of the pandemic and will drive policy and regulatory requirements of the future.

M7: How can healthcare organizations balance the need for financial sustainability with the imperative to provide high-quality care? Please shed light.
KR:
This is a tough one for independent practices. Not only did they not go to school to manage a host of software solutions, they also didn't go to school to be small business owners. So these are all new things for them. They often find themselves struggling to wrap their arms around all the software solutions they need to run their small business, from their EHR to billing and payroll systems.  Being a small business owner wrangling all these decisions and systems makes it particularly challenging to survive as an independent healthcare practice. Of course, the rate at which they can see patients is the heart of their survival. When they look at what's impeding their ability to provide the quality care that they want, they want an efficient way to get rid of roadblocks, while increasing their revenue.

We must improve the clinical and billing healthcare software solutions. They must become more automated, and become more streamlined, so providers can spend their time caring for patients and getting the quality, maximum throughput they expect At Tebra, we truly believe we are a partner, an enabler to them, taking care of running their business while they do what they need to focus on, which is patient care.

M7: What are the latest trends in healthcare management, and what all problems do they aim to solve?
KR: 
AI has always been top of mind for us; this is not a new topic by any means. AI is definitely something we need to leverage, and it’s something we talk about regularly at Tebra. AI is leveraged by most industries and can be a powerful tool to bring automation and innovation to the healthcare space. We need to marry machine learning with AI. That is super critical to making a true difference. AI is only as smart as the data and the people behind it. In any scenario, it can only produce quality content based on the data that it's leveraging in the first place.
There are tons of ideas - we have to leverage these technologies to improve efficiency and drive new value in automation.

The other big advancement that is a consistent theme with the survival of a small business independent practice is around the desire for an all-in-one software platform. When providers are dealing with 15-point solutions that don't talk to each other, it’s very stressful and costly. They end up duplicating data and data entry, and it's very inefficient. So what we've done at Tebra is exactly what the market wants. Providers want one complete operating solution where all of these transition points along the journey of patient care and billing are seamless, and they can see the whole lifecycle. What's really great is, in the end, we're going to be able to show a provider the kinds of metrics that we track as a business, like lifetime value. We will be able to show them what it cost them to acquire that patient and how much value they have gotten from that patient. As a business, it'll be really quite ground breaking.

M7:  How does your organization ensure the privacy and security of patient data?
KR:
We take our clients’ privacy and patient data very seriously at Tebra. You can actually never be too careful. We engage external certified bodies and independent auditors to ensure that the Tebra environment meets or exceeds applicable regulatory requirements and industry best practices. We also regularly give webinars and share thought leadership with our clients to make sure they are current with cybersecurity best practices, such as keeping software updated, using a password manager, and enabling multi-factor authentication.

Read more: Q&A with Fredrik Sundberg, Global Director Strategic Customer Relations at Cytiva


It's very arduous today for patients to have a seamless healthcare experience with the various doctors they see who are using different types of technology systems.

M7: According to you, what are the best practices that modern healthcare entities should adopt to serve patients better?
KR:
 An all-in-one solution is a best practice because it gives providers improved efficiency. After they adopt it, they'll have a lower operating cost of their business and an overall less stressful and simpler life. In turn, patients will have improved quality care since their doctor can be more focused on them and have an overall better experience.
 
M7: Brief us about Tebra’s solutions.
KR:
In 2021, with a combined mission to unlock better healthcare, Kareo and PatientPop joined forces to form Tebra — the operating system for the connected practice of the future. With an all-in-one, purpose-built platform to drive practice success and modernize every step of the patient journey, Tebra provides digital tools and support to attract new patients, deliver modern care, get paid quickly, and operate efficiently. Tebra helps providers meet the needs of the modern healthcare landscape and makes it easier for their patients to access the care they need and have grown to expect from their providers.Kareo, a Tebra company, enables powerful EHR and telehealth solutions, as well as helps providers manage billing and payments and much more. PatientPop, a Tebra company, helps those providers grow their business with leading marketing solutions and communicates with their patients via two-way texting, online scheduling, and a patient portal.

M7: How has the pandemic impacted healthcare policy and regulations?
KR:
One positive thing that came from the COVID-19 pandemic was the fact that there were policy changes. For example, telehealth visits have become reimbursable.Prior to that, they weren't really considered official appointments, and it was very difficult for a provider to receive payment from a telehealth visit. That's all completely changed. It started off as a temporary reimbursement, and then only recently has extended. While it's still not officially permanent, It is anticipated to become a permanent change. I think interoperability has also continued to be reinforced by the results of the pandemic and will drive policy and regulatory requirements of the future.

M7: How has Tebra evolved since its founding, and what are its plans for future growth?
KR:
Tebra now has more than 1,000 employees dedicated to supporting 170k providers who provide care to 113M patients across the country. Since its inception, Tebra has mainly served smaller practices, but the company has been incrementally expanding its service to larger ones of up to 20 doctors. Tebra is also currently expanding the number of medical specialties it supports, an initiative fueled by its new capital injection from Golub Capital in 2021, which earned the company unicorn status.

As it works to develop an end-to-end platform to modernize healthcare practices, Tebra is investing first and foremost in completing the combination of Kareo and PatientPop’s software. The company is also scaling across sales and marketing with the goal of expanding its platform’s network. Additionally, Tebra plans to build out new capabilities for its SaaS platform to extend its business into new areas, including developing card-payment software and entering the fintech space. It also is creating a consumer-facing facet of its platform where patients would be able to easily find local, in-network healthcare providers.  

ABOUT TEBRA

Tebra provides digital tools and assistance for independent healthcare practices to flourish in the new era of healthcare. Tebra is always looking ahead in order to support healthcare providers with solutions for the future. In their mission to facilitate the success of medical practices, the company provides comprehensive solutions for practice operations and growth through their two flagship products, Kareo and PatientPop. To know more please visit: https://www.tebra.com/

More THOUGHT LEADERS

Q&A with Craig Misrach, President and Board Member at UpLyft

Media 7 | December 8, 2020

Craig Misrach, President and Board Member at UpLyft joined the organization in 2018, spearheading the company's product launch and commercialization efforts. He began his career at Deloitte where he audited various lower middle-market businesses as a Senior Accountant. Maintaining an active Certified Public Accountant (CPA) license, Mr. Misrach serves on the Board of Directors of Aculief and the Jewish Community Foundation, San Diego. MEDIA 7: Could you tell us about your career journey from Deloitte to UpLyft? CRAIG MISRACH: I started my career at Deloitte as a public accountant and auditor just trying to get the work experience necessary to obtain my CPA license in the State of California. Little did I know how working in janitor closets at client’s office locations whereby doing your job entailed asking questions and information requests from people who didn’t want to talk to you could build so much character! I left Deloitte to join my client Silvergate Bank where I was the Controller in charge of managing ~$500M in assets at the age of 25. Not only did I gain management responsibility at Silvergate overseeing and working with a staff of 9 individuals, but I also was able to observe first-hand what it was like working in a fast-paced growing entrepreneurial culture as we grew from ~20 to ~70 employees in a short two year period. I decided to go obtain my MBA at the University of Virginia to round out my skill sets and start a new business from the ground up. This was not a traditional path to do so at the time as most graduate students would go get their MBA from a top-tier program to become an investment banker, management consultant, or marketing manager at a Fortune 500 company. I knew from the time early in my career, and in watching my father start his own real estate business growing up in Ohio, that with hard work and perseverance I could start a successful business from the ground up. I started my first venture, Freedom Meditech, by way of learning about the diabetes field in my MBA program and researching the reasons why it was still status quo (not just in 2006 but also still today 15 years later) for people with diabetes to be pricking their finger to determine their blood glucose information. I thought that was so archaic and not fair to such individuals when there was better technology available (subject to FDA compliance) to obtain this information non-invasively. I spent 8+ years as the Founding CEO of Freedom Meditech, where under my leadership, we became the 1st company in the world to obtain FDA clearance for a non-invasive diabetes diagnostic test. The test worked by shining light in a person’s eye for 6 seconds. It was truly revolutionary and the FDA clearance we obtained (the first in the world – we estimated $1B of venture capital went into failed attempts of companies to obtain this FDA clearance and commercialize) was likely one the proudest moments in my career because it was a team effort and a culmination of hard work, numerous late nights, and extremely tough decisions along the way of reducing to practice a prototype, conducting clinical studies, analyzing data, and performing this process all over again several times to support our FDA submission. We built an entire sales organization, international distribution network, sold millions of dollars of product around the world, and then eventually sold the business to Sinocare LTD in China. Our product (ClearPath DS-120) is still used to this day to early detect diabetes and pre-diabetes in patients by clinicians all over the world. The past 5 years I have spent “giving back” to entrepreneurs and the community by way of participating on Boards of Directors and mentoring aspiring entrepreneurs. This includes positions I have held as a board member on Aculief (sold – June 2020), as a Business/Finance mentor for the San Diego Sports Innovation network, and as a Board Member for the Jewish Community Foundation in San Diego. I was introduced to UpLyft and our Founder in 2018. I was skeptical at first of the product mostly because I was not familiar with the field and I did not have a frame of reference for how “unique” UpLyft was or the value proposition it embodied. With an investor mentality, I performed due diligence on the durable medical equipment (DME) landscape, other “lifts” on the market for transferring individuals from bedside to wheelchair, and the size of the market opportunity in the US and around the world. Additionally, I had the benefit of being introduced to the company by my contract manufacturer at my last venture (who was slated to be the contract manufacturer for UpLyft), and that helped gain the confidence that we could manufacture UpLyft with impeccable quality, reasonable cost basis, and in a reasonable timeline. I then signed on to be UpLyft’s President and CEO and since that time we have raised capital, performed extensive customer validation (both for the direct to consumer home market and the for the institutional healthcare facility marketplace), accepted pre-orders from customers, and now are staging the business and technology for mass manufacturing in an FDA-compliant manner. M7:  UpLyft is the world’s first Self Transfer System from bed to wheelchair for people with limited mobility. What are the challenges you faced to launch a high-tech innovation like this? CM: Just like any pre-revenue medical device venture, capitalization is key, and you need to kiss a lot of frogs to obtain the capital necessary to invest in manufacturing so you can mass scale your product. Some refer to this as the valley of death. Initially, we were getting lots of questions on customer validation. Things like “the data suggests this will be a huge success, but we have no proof that customers will be this.” Accordingly, we embarked on several initiatives including: 1. Circulation of surveys to potential customers (and family members, caregivers, and healthcare facility workers) to ascertain what was most important from a product feature, utility, and pricing perspective. Check out our B2B Healthcare Facilities for Nurses/Caregivers. 2. Providing in-person demonstrations where we captured testimonials of use and purchase interest. 3. Creating video content of UpLyft in use (seeing is believing). 4. After securing some angel capital that we could devote to efforts outside of R&D prototype creation and patent filing costs, we were able to establish a digital footprint in 2020 (website, order taking capability, e-mail outreach, social media utility, and engagement) whereby actual customer interest could be measured via open pre-order commitments. With this customer validation now in hand, we believe we can be successful in obtaining the necessary capital (and reducing financing risk) to commence manufacturing and finally provide our pre-order customers and other potential customers a delivery date certain so they have the confidence to place a deposit with us and manufacture and deliver products to them. ...

Read More

Q&A with Fredrik Sundberg, Global Director Strategic Customer Relations at Cytiva

Media 7 | September 17, 2021

Fredrik Sundberg, Global Director Strategic Customer Relations at Cytiva, is responsible for working with the pharmaceutical industry to improve current workflows with innovative bioanalytical solutions. He also advises on R&D projects and business development activities. Fredrik is the author of several publications on drug discovery and biosimilar strategies. He is also a member of an EMEA Pharmaceutical Industry Expert Panel, and he lectures and discusses regulatory issues with government officials and health authorities....

Read More

Q&A with Cecil Nick, Vice President at Parexel

Media 7 | August 2, 2021

Cecil Nick, Vice President (Biotechnology) at Parexel, is a biochemistry graduate and regulatory professional with over 30 years experience specializing in the clinical development of biological and biotech products. He has supported 7 biosimilar marketing approvals and has over 80 biosimilar Agency interactions in EU, US, Canada and RoW. He offers extensive expertise to clients with respect to biosimilars, comparabilty, clinical development, orphan drugs and training. He is a fellow of TOPRA and has been a guest lecture at Cardiff University for MSc in Clinical Research, and Greenwich University for MSc in Pharmaceutical Sciences, courses and Biotech Module leader for the TOPRA MSc course. He was on the editorial panel of SCRIP Clinical Research and has over 30 publications to his name....

Read More

Q&A with Craig Misrach, President and Board Member at UpLyft

Media 7 | December 8, 2020

Craig Misrach, President and Board Member at UpLyft joined the organization in 2018, spearheading the company's product launch and commercialization efforts. He began his career at Deloitte where he audited various lower middle-market businesses as a Senior Accountant. Maintaining an active Certified Public Accountant (CPA) license, Mr. Misrach serves on the Board of Directors of Aculief and the Jewish Community Foundation, San Diego. MEDIA 7: Could you tell us about your career journey from Deloitte to UpLyft? CRAIG MISRACH: I started my career at Deloitte as a public accountant and auditor just trying to get the work experience necessary to obtain my CPA license in the State of California. Little did I know how working in janitor closets at client’s office locations whereby doing your job entailed asking questions and information requests from people who didn’t want to talk to you could build so much character! I left Deloitte to join my client Silvergate Bank where I was the Controller in charge of managing ~$500M in assets at the age of 25. Not only did I gain management responsibility at Silvergate overseeing and working with a staff of 9 individuals, but I also was able to observe first-hand what it was like working in a fast-paced growing entrepreneurial culture as we grew from ~20 to ~70 employees in a short two year period. I decided to go obtain my MBA at the University of Virginia to round out my skill sets and start a new business from the ground up. This was not a traditional path to do so at the time as most graduate students would go get their MBA from a top-tier program to become an investment banker, management consultant, or marketing manager at a Fortune 500 company. I knew from the time early in my career, and in watching my father start his own real estate business growing up in Ohio, that with hard work and perseverance I could start a successful business from the ground up. I started my first venture, Freedom Meditech, by way of learning about the diabetes field in my MBA program and researching the reasons why it was still status quo (not just in 2006 but also still today 15 years later) for people with diabetes to be pricking their finger to determine their blood glucose information. I thought that was so archaic and not fair to such individuals when there was better technology available (subject to FDA compliance) to obtain this information non-invasively. I spent 8+ years as the Founding CEO of Freedom Meditech, where under my leadership, we became the 1st company in the world to obtain FDA clearance for a non-invasive diabetes diagnostic test. The test worked by shining light in a person’s eye for 6 seconds. It was truly revolutionary and the FDA clearance we obtained (the first in the world – we estimated $1B of venture capital went into failed attempts of companies to obtain this FDA clearance and commercialize) was likely one the proudest moments in my career because it was a team effort and a culmination of hard work, numerous late nights, and extremely tough decisions along the way of reducing to practice a prototype, conducting clinical studies, analyzing data, and performing this process all over again several times to support our FDA submission. We built an entire sales organization, international distribution network, sold millions of dollars of product around the world, and then eventually sold the business to Sinocare LTD in China. Our product (ClearPath DS-120) is still used to this day to early detect diabetes and pre-diabetes in patients by clinicians all over the world. The past 5 years I have spent “giving back” to entrepreneurs and the community by way of participating on Boards of Directors and mentoring aspiring entrepreneurs. This includes positions I have held as a board member on Aculief (sold – June 2020), as a Business/Finance mentor for the San Diego Sports Innovation network, and as a Board Member for the Jewish Community Foundation in San Diego. I was introduced to UpLyft and our Founder in 2018. I was skeptical at first of the product mostly because I was not familiar with the field and I did not have a frame of reference for how “unique” UpLyft was or the value proposition it embodied. With an investor mentality, I performed due diligence on the durable medical equipment (DME) landscape, other “lifts” on the market for transferring individuals from bedside to wheelchair, and the size of the market opportunity in the US and around the world. Additionally, I had the benefit of being introduced to the company by my contract manufacturer at my last venture (who was slated to be the contract manufacturer for UpLyft), and that helped gain the confidence that we could manufacture UpLyft with impeccable quality, reasonable cost basis, and in a reasonable timeline. I then signed on to be UpLyft’s President and CEO and since that time we have raised capital, performed extensive customer validation (both for the direct to consumer home market and the for the institutional healthcare facility marketplace), accepted pre-orders from customers, and now are staging the business and technology for mass manufacturing in an FDA-compliant manner. M7:  UpLyft is the world’s first Self Transfer System from bed to wheelchair for people with limited mobility. What are the challenges you faced to launch a high-tech innovation like this? CM: Just like any pre-revenue medical device venture, capitalization is key, and you need to kiss a lot of frogs to obtain the capital necessary to invest in manufacturing so you can mass scale your product. Some refer to this as the valley of death. Initially, we were getting lots of questions on customer validation. Things like “the data suggests this will be a huge success, but we have no proof that customers will be this.” Accordingly, we embarked on several initiatives including: 1. Circulation of surveys to potential customers (and family members, caregivers, and healthcare facility workers) to ascertain what was most important from a product feature, utility, and pricing perspective. Check out our B2B Healthcare Facilities for Nurses/Caregivers. 2. Providing in-person demonstrations where we captured testimonials of use and purchase interest. 3. Creating video content of UpLyft in use (seeing is believing). 4. After securing some angel capital that we could devote to efforts outside of R&D prototype creation and patent filing costs, we were able to establish a digital footprint in 2020 (website, order taking capability, e-mail outreach, social media utility, and engagement) whereby actual customer interest could be measured via open pre-order commitments. With this customer validation now in hand, we believe we can be successful in obtaining the necessary capital (and reducing financing risk) to commence manufacturing and finally provide our pre-order customers and other potential customers a delivery date certain so they have the confidence to place a deposit with us and manufacture and deliver products to them. ...

Read More

Q&A with Fredrik Sundberg, Global Director Strategic Customer Relations at Cytiva

Media 7 | September 17, 2021

Fredrik Sundberg, Global Director Strategic Customer Relations at Cytiva, is responsible for working with the pharmaceutical industry to improve current workflows with innovative bioanalytical solutions. He also advises on R&D projects and business development activities. Fredrik is the author of several publications on drug discovery and biosimilar strategies. He is also a member of an EMEA Pharmaceutical Industry Expert Panel, and he lectures and discusses regulatory issues with government officials and health authorities....

Read More

Q&A with Cecil Nick, Vice President at Parexel

Media 7 | August 2, 2021

Cecil Nick, Vice President (Biotechnology) at Parexel, is a biochemistry graduate and regulatory professional with over 30 years experience specializing in the clinical development of biological and biotech products. He has supported 7 biosimilar marketing approvals and has over 80 biosimilar Agency interactions in EU, US, Canada and RoW. He offers extensive expertise to clients with respect to biosimilars, comparabilty, clinical development, orphan drugs and training. He is a fellow of TOPRA and has been a guest lecture at Cardiff University for MSc in Clinical Research, and Greenwich University for MSc in Pharmaceutical Sciences, courses and Biotech Module leader for the TOPRA MSc course. He was on the editorial panel of SCRIP Clinical Research and has over 30 publications to his name....

Read More

Related News

DIGITAL HEALTHCARE

CarepathRx Health System Solutions and Evernorth Health Services Forge Strategic Partnership to Enhance Specialty Care for Patients

PRNewswire | June 02, 2023

CarepathRx Health System Solutions, a CarepathRx company and portfolio company of Nautic Partners (Nautic), and Evernorth Health Services, a subsidiary of The Cigna Group announced a new strategic partnership and investment by Evernorth in CHSS. The strategic partnership brings together Evernorth's diverse specialty and care expertise with CHSS' robust pharmacy and infusion management capabilities, technology solutions, and health system relationships to improve, expand, and accelerate pharmacy care delivery for the growing number of patients with chronic and complex care needs. The CHSS and Evernorth partnership will deliver integrated specialty pharmacy care to CHSS' growing base of 600-plus hospitals, health systems, and physicians – helping diversify the services they offer to best support patients. This includes enhanced coordinated infusion services, virtual care capabilities, value-based care arrangements, and site of care flexibility. Evernorth's expansive suite of services, including Accredo's specialty care and pharmacy expertise and CuraScript SD's specialty medication distribution across 12,000 physicians, is highly complementary to CHSS' capabilities that help health systems expand in-house specialty pharmacies, infusion and polypharmacy services. "Forging deeper relationships with physicians and other specialty and infusion pharmacies – a critical point of care for people with chronic and complex needs – is a key priority as we work to increase access to care and improve affordability," said Eric Palmer, President and CEO, Evernorth. "Specialty care continues to be a focal point for hospital, health system, and physician partners, and our collaboration with CHSS is an important step in delivering on our commitment to bring them even more patient care services to improve overall outcomes." Together, over time, CHSS' and Evernorth's expertise will help enable simpler, faster connections to care for patients managing chronic and complex specialty conditions. As many of these patients need specialty or acute drug therapies, the partnership will focus on continuity of care for specialty drugs, management of infusion services across sites of care – from ambulatory to physician office to home settings – and value-based site-of-care strategies. The intent is to drive optimal patient treatment plans and deepen physician engagement, resulting in better patient experiences, more care extensions, and greater affordability. "At CarepathRx, we believe health systems, hospitals, and physicians play the most important roles in providing the best care to patients with chronic and complex diseases," said John Figueroa, Chairman and CEO, CarepathRx. "Through specialty and infusion pharmacy partnerships, CHSS has created a model for health systems to extend their reach to alternate sites of care and into the home. This partnership with Evernorth is truly unique and will accelerate CHSS' mission by creating payer-physician connections and leveraging Evernorth's specialty and care services." Centerview Partners acted as lead financial advisor and Cantor Fitzgerald is also acting as financial advisor to CarepathRx and Nautic. Kirkland & Ellis LLP acted as legal advisor to CarepathRx and Nautic. Greenhill & Co. acted as financial advisor to Evernorth. Wachtell, Lipton, Rosen & Katz and Quarles & Brady LLP acted as legal advisors to Evernorth. About CarepathRx CarepathRx is transforming pharmacy care delivery for health systems and hospitals, delivering improved patient outcomes that drive clinical, quality, and financial results. Through the industry's most comprehensive, end-to-end hospital pharmacy care delivery model, CarepathRx is turning hospital pharmacy into an active care management strategy and revenue generator while providing support across the patient's complete healthcare journey. The company takes an enterprise approach, providing a powerful combination of technology, market-leading clinical pharmacy services, and wrap-around services that optimize pharmacy performance across the enterprise for fully integrated pharmacy operations, expanded healthcare services, improved ambulatory access, minimized clinical variation, and new health system revenue streams. Today, CarepathRx serves more than 25 health systems and 600 hospitals, with more than 1,500 employees nationwide.

Read More

HEALTHCARE ANALYTICS

Forbes Review Acknowledges CareCloud as Ideal Solution for Small and Large Practices

Globenewswire | May 30, 2023

CareCloud, Inc. a leader in healthcare technology solutions for medical practices and health systems nationwide, announced it has received a favorable review by Forbes. Forbes highlighted CareCloud’s ability to cater to both small and large practices while offering advanced analtics to facilitate data-driven decision making. In an article published in Forbes Advisor, the renowned business publication highlights CareCloud's user-friendly, comprehensive features and its ability to streamline operations for medical practices of all sizes. The review applauds CareCloud's user-friendly interface, advanced billing capabilities, and robust reporting tools, which enable healthcare providers to optimize their practice efficiency and financial performance. The review notes CareCloud's intuitive scheduling module, which facilitates appointment management and reduces patient wait times. Additionally, the software's mobile app enables healthcare providers to access patient records, schedule appointments, and submit claims on-the-go, enhancing the flexibility and convenience for medical professionals. CareCloud’s solutions reviewed by Forbes include CareCloud Concierge: a revenue cycle management solution that relieves the burden of collections, empowers providers to prioritize patient care, and boosts profitability while eliminating administrative complexities. CareCloud Central: a medical practice management solution that automates daily tasks, eliminates office management bottlenecks, and goes beyond medical billing software to streamline workflows, facilitate seamless department handoffs, and provide real-time analytics for informed business performance. CareCloud Charts: the user-friendly and intuitive electronic health record that revolutionizes healthcare management with its robust reporting, analytics, and customizable features. This empowers providers to gain valuable insights into patient care and practice performance, while seamlessly integrating with third-party applications for streamlined data exchange and improved interoperability. Forbes also highlights the effectiveness of tools like CareCloud Breeze and CareCloud Live. Breeze is a mobile patient portal that simplifies patient registration, intake, and check-ins, and offers a convenient payment platform. With customizable electronic intake forms and preregistration, CareCloud Breeze optimizes efficiency by saving time for office staff and reducing in-office wait times. Live is a telehealth portal enabling secure HIPAA-compliant video calls between practiioners and patients. Compatible with multimple platforms, CareCloud Live ensures easy access and facilitates secure two-way interactions for remote healthcare services. "CareCloud’s aim is to consistently offer cost-effective and innovative solutions that cater to medical practices of all sizes,” said Carinda Cox, vice president of sales at CareCloud. "We are unwavering in our commitment to continuously improve these solutions, ensuring they offer the utmost support for practices to deliver enhanced care. We are honored to receive such commendation from Forbes, a globally trusted source of business information. Moving forward, we will continue to deliver solutions and services that exceed expectations and set new standards." About CareCloud CareCloud brings disciplined innovation to the business of healthcare. Our suite of technology-enabled solutions helps clients increase financial and operational performance, streamline clinical workflows and improve the patient experience. More than 40,000 providers count on CareCloud to improve patient care, while reducing administrative burdens and operating costs. Learn more about our products and services, including revenue cycle management (RCM), practice management (PM), electronic health records (EHR), business intelligence, patient experience management (PXM) and digital health

Read More

HEALTH TECHNOLOGY

Apollo Launches Next-Generation Platform for Rapid Insights in Healthcare and Life Sciences

Businesswire | June 01, 2023

Apollo Intelligence (Apollo), a leading provider of real-time global data and insights to the healthcare and life science industries, announces the launch of its next-generation market insights technology platform to support rapid insights and data collection in the healthcare and life science industries. The advanced platform is fueled by the company’s ongoing investments in its core technologies, propelled by machine learning (ML) and artificial intelligence (AI). With a modern enterprise data architecture, built from best-in-class technologies, Apollo’s next-generation platform provides customers with advanced capabilities to support their progressive insight and data needs. The platform uses ML sampling intelligence to reach global healthcare professional (HCP) panelists with higher efficiency, offering the right research opportunities to the right HCP stakeholders, at the right place and time. This new, advanced capability fosters a seamless cycle of targeted interaction and ongoing engagement that enables greater speed-to-insight and higher quality data. For HCPs, Apollo’s enhanced routing capabilities mean they receive more relevant and matched opportunities to share their expertise and amplify their voice. Capabilities currently rolling out in beta include natural language processing (NLP) advancements in open text analysis for tagging, coding, ML-enhanced adverse event (AE) detection, and reporting. ML-based honoraria optimization for panel engagement. dynamic profiling and validation. In the second half of 2023, these foundational capabilities will support further ML and AI advancements focused on sentiment analysis for free text, survey automation, and expanded global capabilities. “Apollo has been on a multi-year, multimillion-dollar journey building towards this moment when our investments in data and technology would allow us to take advantage of advances in machine learning and data science applications to provide our clients with an unmatched service experience,” said Daniel S. Fitzgerald, president and CEO of Apollo Intelligence. “Life science companies will be able to see the immediate impact in speed and data quality as we leverage machine learning to intelligently sample our HCP communities for data collection. These advances are just the beginning for Apollo as we continue our innovative journey and extend our robust roadmap to deliver higher quality data, speed-to-insight, and advanced analytics and data visualization for our clients.” Apollo has made sizable investments in its platform since 2019 in anticipation of this launch. Its relationship with Frazier Healthcare Partners, in June 2022, has accelerated investment in these areas, with Frazier and Apollo sharing a vision for technological innovation within the healthcare data and insights market. The Frazier Data and AI Center of Excellence has been an instrumental partner in rapidly advancing these modern elements and realizing Apollo’s technology vision. Apollo Intelligence Apollo’s mission is to accelerate health innovation to improve life. In 2019, Apollo launched with the acquisition of InCrowd, a pioneer of real-time, automated insights for the life science industry. In 2020, Apollo strengthened its global reach by acquiring Survey Healthcare Global, a global market leader of first-party healthcare data collection and custom survey solutions. Apollo provides access to 2 million healthcare stakeholders worldwide—including physicians, patients, caregivers, and allied healthcare professionals. Apollo’s 250+ employees support top global pharmaceutical brands, market research agencies, and consultancies across 13 different countries in the Americas, Europe, and Asia. Apollo is a portfolio company of Frazier Healthcare Partners.

Read More

DIGITAL HEALTHCARE

CarepathRx Health System Solutions and Evernorth Health Services Forge Strategic Partnership to Enhance Specialty Care for Patients

PRNewswire | June 02, 2023

CarepathRx Health System Solutions, a CarepathRx company and portfolio company of Nautic Partners (Nautic), and Evernorth Health Services, a subsidiary of The Cigna Group announced a new strategic partnership and investment by Evernorth in CHSS. The strategic partnership brings together Evernorth's diverse specialty and care expertise with CHSS' robust pharmacy and infusion management capabilities, technology solutions, and health system relationships to improve, expand, and accelerate pharmacy care delivery for the growing number of patients with chronic and complex care needs. The CHSS and Evernorth partnership will deliver integrated specialty pharmacy care to CHSS' growing base of 600-plus hospitals, health systems, and physicians – helping diversify the services they offer to best support patients. This includes enhanced coordinated infusion services, virtual care capabilities, value-based care arrangements, and site of care flexibility. Evernorth's expansive suite of services, including Accredo's specialty care and pharmacy expertise and CuraScript SD's specialty medication distribution across 12,000 physicians, is highly complementary to CHSS' capabilities that help health systems expand in-house specialty pharmacies, infusion and polypharmacy services. "Forging deeper relationships with physicians and other specialty and infusion pharmacies – a critical point of care for people with chronic and complex needs – is a key priority as we work to increase access to care and improve affordability," said Eric Palmer, President and CEO, Evernorth. "Specialty care continues to be a focal point for hospital, health system, and physician partners, and our collaboration with CHSS is an important step in delivering on our commitment to bring them even more patient care services to improve overall outcomes." Together, over time, CHSS' and Evernorth's expertise will help enable simpler, faster connections to care for patients managing chronic and complex specialty conditions. As many of these patients need specialty or acute drug therapies, the partnership will focus on continuity of care for specialty drugs, management of infusion services across sites of care – from ambulatory to physician office to home settings – and value-based site-of-care strategies. The intent is to drive optimal patient treatment plans and deepen physician engagement, resulting in better patient experiences, more care extensions, and greater affordability. "At CarepathRx, we believe health systems, hospitals, and physicians play the most important roles in providing the best care to patients with chronic and complex diseases," said John Figueroa, Chairman and CEO, CarepathRx. "Through specialty and infusion pharmacy partnerships, CHSS has created a model for health systems to extend their reach to alternate sites of care and into the home. This partnership with Evernorth is truly unique and will accelerate CHSS' mission by creating payer-physician connections and leveraging Evernorth's specialty and care services." Centerview Partners acted as lead financial advisor and Cantor Fitzgerald is also acting as financial advisor to CarepathRx and Nautic. Kirkland & Ellis LLP acted as legal advisor to CarepathRx and Nautic. Greenhill & Co. acted as financial advisor to Evernorth. Wachtell, Lipton, Rosen & Katz and Quarles & Brady LLP acted as legal advisors to Evernorth. About CarepathRx CarepathRx is transforming pharmacy care delivery for health systems and hospitals, delivering improved patient outcomes that drive clinical, quality, and financial results. Through the industry's most comprehensive, end-to-end hospital pharmacy care delivery model, CarepathRx is turning hospital pharmacy into an active care management strategy and revenue generator while providing support across the patient's complete healthcare journey. The company takes an enterprise approach, providing a powerful combination of technology, market-leading clinical pharmacy services, and wrap-around services that optimize pharmacy performance across the enterprise for fully integrated pharmacy operations, expanded healthcare services, improved ambulatory access, minimized clinical variation, and new health system revenue streams. Today, CarepathRx serves more than 25 health systems and 600 hospitals, with more than 1,500 employees nationwide.

Read More

HEALTHCARE ANALYTICS

Forbes Review Acknowledges CareCloud as Ideal Solution for Small and Large Practices

Globenewswire | May 30, 2023

CareCloud, Inc. a leader in healthcare technology solutions for medical practices and health systems nationwide, announced it has received a favorable review by Forbes. Forbes highlighted CareCloud’s ability to cater to both small and large practices while offering advanced analtics to facilitate data-driven decision making. In an article published in Forbes Advisor, the renowned business publication highlights CareCloud's user-friendly, comprehensive features and its ability to streamline operations for medical practices of all sizes. The review applauds CareCloud's user-friendly interface, advanced billing capabilities, and robust reporting tools, which enable healthcare providers to optimize their practice efficiency and financial performance. The review notes CareCloud's intuitive scheduling module, which facilitates appointment management and reduces patient wait times. Additionally, the software's mobile app enables healthcare providers to access patient records, schedule appointments, and submit claims on-the-go, enhancing the flexibility and convenience for medical professionals. CareCloud’s solutions reviewed by Forbes include CareCloud Concierge: a revenue cycle management solution that relieves the burden of collections, empowers providers to prioritize patient care, and boosts profitability while eliminating administrative complexities. CareCloud Central: a medical practice management solution that automates daily tasks, eliminates office management bottlenecks, and goes beyond medical billing software to streamline workflows, facilitate seamless department handoffs, and provide real-time analytics for informed business performance. CareCloud Charts: the user-friendly and intuitive electronic health record that revolutionizes healthcare management with its robust reporting, analytics, and customizable features. This empowers providers to gain valuable insights into patient care and practice performance, while seamlessly integrating with third-party applications for streamlined data exchange and improved interoperability. Forbes also highlights the effectiveness of tools like CareCloud Breeze and CareCloud Live. Breeze is a mobile patient portal that simplifies patient registration, intake, and check-ins, and offers a convenient payment platform. With customizable electronic intake forms and preregistration, CareCloud Breeze optimizes efficiency by saving time for office staff and reducing in-office wait times. Live is a telehealth portal enabling secure HIPAA-compliant video calls between practiioners and patients. Compatible with multimple platforms, CareCloud Live ensures easy access and facilitates secure two-way interactions for remote healthcare services. "CareCloud’s aim is to consistently offer cost-effective and innovative solutions that cater to medical practices of all sizes,” said Carinda Cox, vice president of sales at CareCloud. "We are unwavering in our commitment to continuously improve these solutions, ensuring they offer the utmost support for practices to deliver enhanced care. We are honored to receive such commendation from Forbes, a globally trusted source of business information. Moving forward, we will continue to deliver solutions and services that exceed expectations and set new standards." About CareCloud CareCloud brings disciplined innovation to the business of healthcare. Our suite of technology-enabled solutions helps clients increase financial and operational performance, streamline clinical workflows and improve the patient experience. More than 40,000 providers count on CareCloud to improve patient care, while reducing administrative burdens and operating costs. Learn more about our products and services, including revenue cycle management (RCM), practice management (PM), electronic health records (EHR), business intelligence, patient experience management (PXM) and digital health

Read More

HEALTH TECHNOLOGY

Apollo Launches Next-Generation Platform for Rapid Insights in Healthcare and Life Sciences

Businesswire | June 01, 2023

Apollo Intelligence (Apollo), a leading provider of real-time global data and insights to the healthcare and life science industries, announces the launch of its next-generation market insights technology platform to support rapid insights and data collection in the healthcare and life science industries. The advanced platform is fueled by the company’s ongoing investments in its core technologies, propelled by machine learning (ML) and artificial intelligence (AI). With a modern enterprise data architecture, built from best-in-class technologies, Apollo’s next-generation platform provides customers with advanced capabilities to support their progressive insight and data needs. The platform uses ML sampling intelligence to reach global healthcare professional (HCP) panelists with higher efficiency, offering the right research opportunities to the right HCP stakeholders, at the right place and time. This new, advanced capability fosters a seamless cycle of targeted interaction and ongoing engagement that enables greater speed-to-insight and higher quality data. For HCPs, Apollo’s enhanced routing capabilities mean they receive more relevant and matched opportunities to share their expertise and amplify their voice. Capabilities currently rolling out in beta include natural language processing (NLP) advancements in open text analysis for tagging, coding, ML-enhanced adverse event (AE) detection, and reporting. ML-based honoraria optimization for panel engagement. dynamic profiling and validation. In the second half of 2023, these foundational capabilities will support further ML and AI advancements focused on sentiment analysis for free text, survey automation, and expanded global capabilities. “Apollo has been on a multi-year, multimillion-dollar journey building towards this moment when our investments in data and technology would allow us to take advantage of advances in machine learning and data science applications to provide our clients with an unmatched service experience,” said Daniel S. Fitzgerald, president and CEO of Apollo Intelligence. “Life science companies will be able to see the immediate impact in speed and data quality as we leverage machine learning to intelligently sample our HCP communities for data collection. These advances are just the beginning for Apollo as we continue our innovative journey and extend our robust roadmap to deliver higher quality data, speed-to-insight, and advanced analytics and data visualization for our clients.” Apollo has made sizable investments in its platform since 2019 in anticipation of this launch. Its relationship with Frazier Healthcare Partners, in June 2022, has accelerated investment in these areas, with Frazier and Apollo sharing a vision for technological innovation within the healthcare data and insights market. The Frazier Data and AI Center of Excellence has been an instrumental partner in rapidly advancing these modern elements and realizing Apollo’s technology vision. Apollo Intelligence Apollo’s mission is to accelerate health innovation to improve life. In 2019, Apollo launched with the acquisition of InCrowd, a pioneer of real-time, automated insights for the life science industry. In 2020, Apollo strengthened its global reach by acquiring Survey Healthcare Global, a global market leader of first-party healthcare data collection and custom survey solutions. Apollo provides access to 2 million healthcare stakeholders worldwide—including physicians, patients, caregivers, and allied healthcare professionals. Apollo’s 250+ employees support top global pharmaceutical brands, market research agencies, and consultancies across 13 different countries in the Americas, Europe, and Asia. Apollo is a portfolio company of Frazier Healthcare Partners.

Read More

Spotlight

Tebra

The world of medicine is forever evolving, with new demands and challenges around every corner. We're always looking ahead to bring tomorrow's solutions to today's providers. Some might call it foresight or innovation. We call it Tebra....

Events

Resources